Aimmune Therapeutics develops treatments to protect children with food allergies (peanut, milk, and egg) from the consequences of accidental exposure.

Biotechnology

Aimmune Therapeutics

Alicia Goodman has more than 20 years of experience in international and strategic human resources planning, talent acquisition and development, and advancing organizational cultures in pharmaceutical and biotech, consumer goods, and telecommunications. Most recently, Ms. Goodman led the human resources function at [Millendo Therapeutics](/org/millendo-therapeutics), a biotech start-up focused on endocrine diseases. Before that, Ms. Goodman was a principal in a human resources consultancy, during which time she served as ad interim Senior Vice President, Chief People and Culture Officer for Berg IIc, a privately held biotech, as well as ad interim Global Vice President of Human Resources for [Alvogen](/org/alvogen-inc), a privately held pharmaceutical company with commercial operations in 35 countries.Previously, Ms. Goodman was with Novartis for six years, where she held several human resources roles of increasing responsibility, culminating with the position of Vice President of Human Resources for North America Consumer Health. Ms. Goodman holds an MS in human resources from [Central Michigan University](/org/central-michigan-university) and a BA in social science from [Michigan State University](/org/michigan-state-university).

Alicia Goodman

Andrew Oxtoby has over two decades of experience in the health care and consumer products industries, including extensive global pharmaceutical experience with successful product launches, commercialization, and strategic planning. Mr. Oxtoby joined Aimmune in January 2019 as Chief Commercial Officer and built the commercial organization to prepare for the FDA approval and launch of PALFORZIA in January 2020, transforming Aimmune from a clinical-stage organization to a fully integrated commercial-stage biotechnology company. In October 2020, Mr. Oxtoby was appointed President and Chief Executive Officer.

Before joining Aimmune, Mr. Oxtoby spent 16 years at Eli Lilly and Company where, after having served as Vice President of US Diabetes Sales, he was responsible for Lilly’s US insulin business as Vice President of US Diabetes Connected Care and Insulins, an innovative, patient-focused business unit. While at Lilly, he also spent five years in oncology, including as Vice President of the International Oncology business, was General Manager of Lilly’s Netherlands operation, and held positions of increasing responsibility in marketing and sales. Mr. Oxtoby began his career at [Procter & Gamble](/org/procter-gamble), where he spent four years in the engineering and manufacturing organizations. Mr. Oxtoby has an MBA from [Harvard Business School](/org/harvard-business-school) and a BS in mechanical engineering from [Purdue University](/org/purdue-university).

Andrew Oxtoby

Moreno Perugini is currently the SVP of Global Medical Affairs at [Aimmune Therapeutics](/org/aimmune-therapeutics). Moreno has extensive experience in the pharmaceutical and healthcare industries, having previously served as Vice President Commercial, Market Access and Medical Affairs Pharma at Nestlé Health Science, Head of Global Market Access at Nestle S.A., Head Global HTA Strategy at [Sanofi](/org/sanofi), and Global Senior Director, Value Propostion at [AbbVie](/org/abbvie). Moreno also spent two years as Global Director, Value Propositions at Abbott Labs, and three years as Global Associate Director, Pricing and Market Access at [Novartis](/org/novartis).

Moreno Perugini has a Master's Degree in Pharmacoeconomics/Pharmaceutical Economics from UPF-IDEC, a Regulatory Affairs Certificate from the Regulatory Affairs Professional Society, and a CPP - Certified Pricing Professional from the Professional Pricing Society. Moreno also has an MBA in Pharmaceutical Marketing and Management from UCLA Anderson School of Management and an MPA in Lobbying - Public Affairs and Government Relations from Università LUMSA. Additionally, they have a Master's degree in Health Care services management from Università degli Studi 'Gabriele d'Annunzio'​ di Chieti and a Mmath in Mathematics from Università degli studi Roma TRE.

They work with Paul Spence - SVP, U.S. Pharmaceuticals, Alicia Goodman - SVP, Human Resources, and Jason Burdette - SVP & Head of Technical Operations. Moreno Perugini reports to Andrew Oxtoby, President & CEO.

Moreno Perugini

Jim Pepin has been practicing law for 20 years, with significant experience in the life sciences and consumer goods industries. Prior to joining Aimmune, Mr. Pepin spent over 10 years with Nestlé HealthCare Nutrition, Inc., where he most recently served as its Vice President & General Counsel. As a member of the senior leadership team, he led the Legal & Compliance function of Nestlé’s U.S. healthcare nutrition business, which markets and sells a diverse portfolio of consumer care nutritional products as well as specialized medical nutrition sold directly to hospitals, long-term care facilities and home healthcare providers.Prior to joining Nestlé in 2010, he was Acting General Counsel, Corporate Secretary and Compliance Officer of PDI, Inc., a publicly traded pharmaceutical contract sales organization. Mr. Pepin began his legal career as a corporate attorney at Sullivan & Cromwell LLP in London, England and then at King & Spalding LLP in New York, specializing in corporate finance and securities law. Mr. Pepin earned his B.A. in Foreign Affairs from the University of Virginia and a J.D. from the University of Virginia School of Law.

Jim Pepin

Prior to Aimmune, Steve spent over five years in the Deloitte Life Science M&A Finance practice where he worked with Fortune 500 clients on M&A growth strategy and integration. His integration work focused on standing up the core Finance infrastructure and processes for private equity acquisitions.

Prior to Deloitte, Steve worked as a healthcare investor at a startup private equity fund, HealthCor Partners, and as a healthcare investment banker at Merrill Lynch.

Steve holds a Master of Business Administration from The Wharton School at the University of Pennsylvania, and a Bachelor of Science in Finance from Carnegie Mellon University.

Steve Killmeyer

Nicolas Fouché has 21 years of pharmaceutical and biotechnology experience with the Boston Consulting Group (BCG), [AstraZeneca](/org/astrazeneca), and most recently Gilead. He joined Aimmune in early 2020 as General Manager, France and U.K. to prepare for the launch of PALFORZIA; creating country teams and supporting reimbursement efforts before being promoted in December 2020 to his current position and undertaking the same launch activities across Europe and other geographies in order to bring PALFORZIA to patients worldwide.

Prior to Aimmune, Mr. Fouché’s career spanned positions in Marketing, Sales, Business Development, Strategic Planning, Business Operations and General Management; starting initially as an advisor to pharmaceutical companies at BCG, and then in-market positions in France, the U.K. and Japan, and regional roles across Europe, the Middle East and Africa (EMEA) and Central & Eastern Europe; overseeing dozens of launches of Gilead’s Hepatitis C and HIV medicines; and setting up infrastructures for patients to receive life-saving viral treatment. Mr. Fouché is French and holds a Master of Business Administration from Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC).

Nicolas Fouché

Doug Walker

Jason Burdette

Louise Peacock

Paul Spence has more than 28 years in the healthcare and pharmaceutical market. His highly successful foundation was built upon US and Global roles in marketing, sales, operations, strategy, and commercial leadership sharing his passion for building new teams, launching new models and brands, and leading organizational transformation. Culture and talent development are very important to Paul and central to his approach to leading his teams and partnering cross-functionally. He joined Nestlé Health Science (NHSc) 4 years ago as the Vice President of Medical Nutrition Sales where he transformed his Sales Leadership Team with fast-paced growth initiatives and new GTM models. Most recently he was the Business Executive Officer for NHSc US Pharmaceuticals, leading the integration of Zenpep and Viokace, and developing the NHSc US Pharmaceutical organization and operations across all operating functions in the US and globally.

Previous to NHSc he was with Boehringer-Ingelheim (BI), culminating with the position of Vice President of Sales, South Area. Prior to that he was Executive Director of the Go-to-Market model where he led BI’s national initiative to transform the US medical and commercial customer-facing model to support BI’s long-range forecast, portfolio evolution and marketplace change. Before joining BI, Paul spent 6 years with Sanofi-Aventis where he held several commercial roles to include the build and launch of the Quality Initiatives Organization. His other experience includes marketing, field leadership, and operations roles with Bristol-Myers Squibb and Johnson & Johnson.
Paul earned a BS in finance and accounting from The Pennsylvania State University and an MBA from Villanova University. He also holds several certifications including Six Sigma Green Belt and Loyola University Quality Institute.

Paul Spence

With over 28 years of experience in Compliance and Legal, Ms. Lacerca-Allen has been a leader in developing and implementing global compliance programs within Top Fortune 100 companies. Prior to joining Aimmune, Ms. Lacerca-Allen held several leadership positions at Elan, Mylan, Bristol Myers & Squibb, Microsoft, Merck, AT&T Capital and served as a member of the Board of Directors of Arthrocare, a publicly traded company in the medical device industry. Ms. Lacerca-Allen has extensive experience delineating compliance strategy, leading global teams and negotiating, implementing and executing corporate integrity agreements, deferred prosecution agreements and consent decrees.She has been recognized by Compliance Week as Top Minds 2019, Hispanic Executive Magazine as Legal Industry Leader and The Guardian as Women in Leadership, Inspiring Leaders. Ms. Lacerca-Allen received her Juris Doctor degree from the Universidad de Buenos Aires and obtained her LLM degree from UCLA where she was the recipient of 1992 UCLA’s tuition waiver based on merit and recognition.

Fabiana Lacerca-Allen

Cathy Nolan has over two decades of experience in the pharmaceutical industry. Prior to joining Aimmune, Ms. Nolan spent 20 years at Eli Lilly and Company, where she was involved in commercial roles in small and large affiliates, global organizations in the US and Europe, and most recently as a Business Unit Leader and Chief Marketing Officer in the UK Hub. Ms. Nolan has deep marketing and commercialization experience and expertise, leading brand building efforts for early phase products in the global organization as well as the commercialization of launch products through to late lifecycle across geographies.Ms. Nolan joined Aimmune as the Executive Director of Global Marketing and Commercial Capabilities and has been a member of the team since November 2019. She has a Bachelor of Commerce Degree and a Higher Diploma in Marketing Practice from the National University of Ireland, Galway.

Aimmune Therapeutics

Org chart

Teams

Leadership Team

CEO and Executive Team

Discover similar companies